Core Viewpoint - China National Pharmaceutical Group (国药控股) reported a slight decline in revenue for the fiscal year 2025, while net profit showed a modest increase, indicating mixed performance across its business segments [1] Financial Performance - The company achieved a revenue of RMB 575.168 billion, representing a year-on-year decrease of 1.6% [1] - Net profit attributable to shareholders was RMB 7.155 billion, reflecting a year-on-year increase of 1.5% [1] - Earnings per share were reported at RMB 2.29, with a proposed final dividend of RMB 0.69 per share [1] Business Segment Analysis - The pharmaceutical distribution segment accounted for 72.79% of total revenue, down 0.37 percentage points year-on-year [1] - The medical device distribution segment contributed 19.32% to revenue, showing a slight decline of 0.09 percentage points [1] - The retail pharmaceutical segment's revenue share increased to 6.42%, up 0.50 percentage points year-on-year [1] Market Expectations - Citigroup's report indicated that the management expects the pharmaceutical distribution business sales to remain flat year-on-year, while medical device distribution and retail businesses are anticipated to recover and achieve positive growth [1] - Citigroup has revised down its revenue forecasts for the company by 3% and 4% for the next two years, reflecting the latest guidance from management [1] - The earnings per share forecast has been adjusted down by 5% for both years, with the target price lowered from HKD 23 to HKD 22.8, while maintaining a "Buy" rating [1]

Group 1 - HSBC has lowered the target price for NVIDIA (NVDA.O) from $320 to $310 [1]

Group 1 - Morgan Stanley has lowered Airbus's target price from €240 to €225 [1]

Group 1 - Wells Fargo has lowered the target price for Workday from $290 to $255 [1]

Group 1 - Citigroup has lowered Broadcom's target price from $480 to $458 while maintaining a "Buy" rating [1]

Group 1 - Barclays Bank maintains a "Hold" rating for Ingredion (INGR.N) and raises the target price from $124 to $128, reflecting expectations of the company's robust performance in the food ingredients sector [1][2] Group 2 - Over the past week (February 6 to February 11, 2026), Ingredion's stock price fluctuated by 0.77%, with a range of 3.86%. The stock reached a high of $121.75 on February 6 and closed at $119.80 on February 11, showing a daily increase of 0.91% [3] - The trading volume during this period was approximately $302 million, indicating a moderate level of trading activity [3]

Group 1 - Morgan Stanley has lowered the target price for Maersk from 8600 Danish Krone to 8500 Danish Krone [1]

Group 1 - Citigroup has lowered the target price for Arm from $200 to $190 [1]

Group 1 - Morgan Stanley has lowered the target price for PayPal (PYPL.O) from $70.00 to $46.00 [1]

Group 1 - Barclays has lowered Abbott's target price from $169 to $142 while maintaining an "Overweight" rating [1]